Intensive HbA1c Control Cuts Diabetic Retinopathy Progression

Share this content:
Intensive HbA1c Control Cuts Diabetic Retinopathy Progression
Intensive HbA1c Control Cuts Diabetic Retinopathy Progression

MONDAY, June 13, 2016 (HealthDay News) -- Intensive blood glucose control appears to reduce the risk of retinopathy progression in patients with type 2 diabetes, according to a study presented at the American Diabetes Association's 76th Scientific Sessions, held from June 10 to 14 in New Orleans.

Researchers compared type 2 diabetes patients who received either intensive therapy or standard therapy for glycemic control. Participants on intensive therapy had average glycated hemoglobin (HbA1c) levels of 6.4 percent when the study ended. The standard therapy group had HbA1c levels that averaged 7.7 percent.

The researchers checked the study volunteers' eye health four years after treatment ended. At that point, HbA1c levels were almost the same -- 7.8 for the intensive group and 7.9 for the standard group. The researchers found that the risk of retinopathy progression for patients in the intensive therapy group was 5.8 percent. In the standard therapy group, that rate was 12.7 percent.

"This study sends a powerful message to people with type 2 diabetes who worry about losing vision," lead author Emily Chew, M.D., deputy director of the division of epidemiology and clinical applications at the U.S. National Eye Institute in Bethesda, Md., said in an institute news release. "Well-controlled glycemia has a positive, measurable, and lasting effect on eye health."

Press Release
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »